Clinical trials
Phase 2 trials in Bosnia and Herzegovina
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
41 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 4 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 24 |
| Recruiting | 7 |
| Terminated | 6 |
| Active, not recruiting | 2 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 6 |
| Pfizer | 6 |
| Central European Cooperative Oncology Group | 2 |
| Alnylam Pharmaceuticals | 1 |
| Altavant Sciences GmbH | 1 |
| Astellas Pharma Inc | 1 |
| Can-Fite BioPharma | 1 |
| Cantonal Hospital Zenica | 1 |
| Chiesi Farmaceutici S.p.A. | 1 |
| Daiichi Sankyo | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Colitis, Ulcerative | 4 |
| Arthritis, Rheumatoid | 3 |
| Breast Neoplasms | 3 |
| Colorectal Neoplasms | 3 |
| Inflammatory Bowel Diseases | 3 |
| Atrial Fibrillation | 2 |
| Crohn Disease | 2 |
| Neoplasm Metastasis | 2 |
| Thromboembolism | 2 |
| Adenocarcinoma | 1 |
Trials
Showing 26 to 41 of 41. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.